Human Genome (HGSI) Slammed After BENLYSTA Fails To Hit Secondary Endpoints and European JOULFERON Application Pulled
Tweet Send to a Friend
Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) have been under heavy pressure today after the company announced that secondary ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
